Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Tim McGraw, Merck and the American Diabetes Association Challenge Americans with Type 2 Diabetes to Get to Their A1C Goal

Platinum-Recording Artist and Actor Rallies People to Make a Pledge with America's Diabetes Challenge: Get to Your Goals Program

America's Diabetes Challenge

News provided by

Merck

Apr 22, 2015, 08:00 ET

Share this article

Share toX

Share this article

Share toX

KENILWORTH, N.J., April 22, 2015 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association, today announced that award-winning artist Tim McGraw, who has loved ones impacted by type 2 diabetes, will travel the country to urge people with the disease to get their blood glucose under control. Together, they are launching America's Diabetes Challenge: Get to Your Goals, an educational program that encourages people with type 2 diabetes to work with their doctor to set and reach their A1C, their average blood glucose level over the past 2 to 3 months. Through the program, people living with type 2 diabetes can also learn if they are at risk of low blood glucose, known as hypoglycemia, and how to help reduce that risk. McGraw is challenging people with type 2 diabetes to take the challenge and make a pledge to get to goal with the support of those who care for them.

Continue Reading
Merck
Merck
American Diabetes Association
American Diabetes Association

"I've seen first-hand how diabetes impacts people from all walks of life, including my family, friends and fans. I'm a strong believer in making healthy choices, which is why I'm teaming up with Merck and the American Diabetes Association on America's Diabetes Challenge," said McGraw. "I've learned that about one-third of adults living with diabetes are not at their A1C goal. I want to change that statistic, so I'm encouraging all Americans to join me. If you have type 2 diabetes, take the challenge and pledge to work with your doctor to set and reach your A1C goal. And, if you're like me and know someone living with type 2 diabetes, challenge them to work with their doctor to get to their goal. Together, we can make a difference."

People with type 2 diabetes can help reduce their risk of serious complications by setting individual goals to help manage the ABCs of diabetes—A for A1C, also known as blood glucose, B for blood pressure and C for cholesterol.

The American Diabetes Association recommends that people with diabetes have an individualized A1C goal; the A1C goal for many adults with diabetes is less than 7 percent. However, a higher or lower goal may be appropriate for some people. High blood glucose levels over time can lead to serious health problems, including heart disease, blindness, kidney failure, lower limb amputations, stroke and nerve problems. That is why, according to the American Diabetes Association, it is so important for people with diabetes to know their A1C and to work with their doctor to set and reach a goal that is right for them.

The American Diabetes Association is committed to raising awareness of diabetes and to providing relevant resources to help people with the disease," said David G. Marrero, PhD, President, Health Care & Education, American Diabetes Association. "We know how difficult it can be for the millions living with diabetes to get to their A1C goal, which is why we're excited to be part of America's Diabetes Challenge, a program that addresses this issue with the aim of making a difference in the lives of people with type 2 diabetes and those who have loved ones with the disease."

Many people with type 2 diabetes are aware of the importance of controlling high blood glucose by diet, exercise, and taking medicine (if prescribed), but they may not know that blood glucose can also go too low. Hypoglycemia can make people feel shaky, dizzy, sweaty and sometimes faint. If left untreated, hypoglycemia may lead to a seizure or loss of consciousness. Many people with type 2 diabetes know that hypoglycemia can be caused by skipping meals or exercising excessively, but what they may not know is that certain diabetes medicines can also cause blood glucose it to go too low. People living with type 2 diabetes should talk to their doctor to learn if they are at risk of hypoglycemia and how they can help reduce their risk. They may need to talk to their doctor about making changes to their treatment plan, including diet, exercise, and diabetes medicine, if appropriate.

"At Merck, we're dedicated to helping people with type 2 diabetes achieve better blood glucose control, and we recognize the important role that a support system plays when it comes to managing this disease," said Arpa Garay, U.S. marketing leader, Diabetes Franchise, Merck. "By collaborating with the American Diabetes Association and Tim McGraw, we look forward to empowering people with type 2 diabetes to work with their doctor to develop a treatment plan that will help them reach their A1C goal and maintain that goal over time. We're also committed to helping people learn if they are at risk of hypoglycemia and how to help reduce that risk."

For more information about America's Diabetes Challenge, to make the pledge to work with your doctor to set and reach your own A1C goal or to challenge loved ones to do the same, visit www.AmericasDiabetesChallenge.com. You can also join the America's Diabetes Challenge community by visiting Facebook.com/AmericasDiabetesChallenge.

About Tim McGraw

Tim McGraw, who is gearing up for his latest tour, has sold more than 40 million records worldwide and dominated the charts with 36 #1 singles. He has won three Grammy Awards, 16 Academy of Country Music Awards, 14 Country Music Association Awards, 10 American Music Awards, three People's Choice Awards and numerous other honors. His iconic career achievements include being named the Broadcast Data Systems (BDS) Most Played Artist of the Decade for all music genres. 

About America's Diabetes Challenge: Get to Your Goals

America's Diabetes Challenge: Get to Your Goals is an educational program from Merck and the American Diabetes Association urging people with type 2 diabetes to work with their doctor to set and reach their individual A1C goal. The program also helps people with type 2 diabetes learn if they are at risk of low blood glucose and how to help reduce that risk. As part of Merck's partnership with the American Diabetes Association, and to further support the millions of Americans living with type 2 diabetes, America's Diabetes Challenge will be featured at American Diabetes Association EXPOs and Live Empowered and Feria de Salud events throughout the U.S. For more information about America's Diabetes Challenge, to make the pledge to work with your doctor to set and reach your own A1C goal or challenge loved ones to do the same, visit www.AmericasDiabetesChallenge.com. You can also join the America's Diabetes Challenge community by visiting Facebook.com/AmericasDiabetesChallenge.

About Type 2 Diabetes

Nearly 30 million Americans have diabetes, and 90% to 95% of these people have type 2 diabetes. When someone has type 2 diabetes, the body does not make enough insulin and/or the insulin that the body makes does not work properly. This causes blood glucose levels to become too high, and the body may also keep making glucose even though it does not need it. Once a person has type 2 diabetes, it does not go away, and high blood glucose levels over time can lead to serious health problems, such as heart disease and stroke.

About the American Diabetes Association

The American Diabetes Association is leading the fight to Stop Diabetes and its consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. For the past 75 years, our mission has been to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Merck Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2014 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Media Contacts:

Pam Eisele

Merck

(267) 305-3558


Megan Wilkinson

Merck

(267) 305-6463

 

Samantha Boyd

American Diabetes

Association

(703) 549-1500 ext. 2139

Investor Contact:

Justin Holko
Merck
(908) 740-1879








Logo - http://photos.prnewswire.com/prnh/20150421/200261LOGO

Logo - http://photos.prnewswire.com/prnh/20150421/200262LOGO

Logo - http://photos.prnewswire.com/prnh/20150421/200263LOGO

SOURCE Merck

Related Links

http://www.merck.com

21%

more press release views with 
Request a Demo

Modal title

Also from this source

Merck führt erste cyber-physische Digital-Trust-Plattform für höhere Produktsicherheit und Schutz vor Produktfälschung am Markt ein

Merck führt erste cyber-physische Digital-Trust-Plattform für höhere Produktsicherheit und Schutz vor Produktfälschung am Markt ein

Merck, ein führendes Wissenschafts- und Technologieunternehmen, hat heute eine Beta-Version von M-Trust™ auf den Markt gebracht. Hierbei handelt es...

Merck lanza la primera plataforma de confianza ciberfísica en el mercado

Merck lanza la primera plataforma de confianza ciberfísica en el mercado

Merck, una empresa líder en ciencia y tecnología, lanzó hoy una versión beta de M-Trust™, una plataforma de confianza ciberfísica segura, creada para ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Supplementary Medicine

Supplementary Medicine

Education

Education

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.